Merck no-go decision spells the end for JT's novel osteoporosis drug
This article was originally published in Scrip
Executive Summary
Merck & Co's decision to end a licensing deal with Japan Tobacco (JT) for a novel therapy for post-menopausal osteoporosis has also prompted the Japanese firm to discontinue its development programme for the oral calcium-sensing receptor antagonist.